Swing Trade Ideas

🏃🚀✅ YCBD high 1.18, over 58%  🚀 

🏃🚀✅ THH high 1.41, over 145%  🚀 

🏃🚀✅ ONCY high 1.21, over 28%  🚀 

🏃🚀✅ VERO high 11.95, over 665%  🚀 

🏃🚀✅NBY 14.84 up over 1245% from low 1  🚀 

🏃🚀✅UAVS 1.82  115%  🚀 

🏃🚀✅MRKR 2.21  58%  🚀 

🏃🚀✅SIDU 5.51  635%  🚀 

 ✅ $UAVS Entry: $1.00 – $1.05

🎯 PT1: $1.20 – $1.50, 🎯 PT2: $1.60 – $2.20,🎯 PT3: $2.30 – $3.20

🚫 Stop: Below $0.80, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 recently delivered First eBee X manufacturing kits to Vyom drones, marking milestone toward local production in India, previously sold eBee VISION Drones to U.S Army in Germany, partnered wit Makville to bring drones to Egypt, company designs and delivers unmanned aerial system including drones, sensors, software and data analytics solutions globally for commercial, government, agricultural, energy, infrastructure, and defense applications, does have mixed shelf, be mindful on next spike 

✅ $BYND Entry: $0.75

🎯 PT1: $1.20 – $1.90,🎯 PT2: $2.05 – $3.8, PT3: $3.90 – $4.50

🚫 Stop: Below $0.70, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast-Moving | Technical Setup

 recently launched latest Beyond Burger at Hard Rock Cafe and introduced Beyond Beef at retailers across Canada, company produces plant-based meat alternatives, does have mixed shelf, be mindful on next spike 

 ✅ $FLD entry: $2.05 – $2.15

🎯 PT1: $2.40 – $2.8, 🎯 PT2: $2.90 – $3.6, 🎯 PT3: $3.70 – $4.30

🚫 Stop: Below $2.00, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast-moving | Technical setup

 back to suport, recently launched No annual fee credit card with up to 4% $BTC.X back monthly , company operates a bitcoin-financial-services platform that enables consumers to earn, save, and use $BTC.X via consumer financial products, recently partnered with Steak n' Shake for BTC.X promotion, CEO previously announced wanting BTC.X gift card to be available in holiday season, Cantor Fitzgerald price target $6.50, Leerink partners price target $14.5, does have mixed shelf, be mindful on next spike  

✅ $LNAI entry: $0.80

🎯 PT1: $1.10 – $1.80, 🎯 PT2: $1.90 – $2.7,  PT3: $2.80 – $3.70

🚫 Stop: Below $0.75, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast-moving | Technical setup

 recently unveiled AI tool to block novel chemical weapon designs, previously expanded NIH-backed AI platform into commercial alcohol use disorder drug discovery, previously identified three Parkinson's disease subtypes and drug targets to accelerate therapeutic development, also recently secured first letter of intent for its immune cell therapy, launched transformer-base platform to secure GenAI, partnered with American Defense International to enhance US. Biodefense capabilities , company is a pre-clinical biotech and AI-powered drug discovery company focused on developing of therapeutics and vaccines, AI-driven diagnostic platforms, and biodefense 

 ✅ $FLD entry: $2.05 – $2.15

🎯 PT1: $2.40 – $2.8, 🎯 PT2: $2.90 – $3.6, 🎯 PT3: $3.70 – $4.30

🚫 Stop: Below $2.00, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast-moving | Technical setup

 back to suport, recently launched No annual fee credit card with up to 4% $BTC.X back monthly , company operates a bitcoin-financial-services platform that enables consumers to earn, save, and use $BTC.X via consumer financial products, recently partnered with Steak n' Shake for BTC.X promotion, CEO previously announced wanting BTC.X gift card to be available in holiday season, Cantor Fitzgerald price target $6.50, Leerink partners price target $14.5, does have mixed shelf, be mindful on next spike  

✅ $LNAI entry: $0.80

🎯 PT1: $1.10 – $1.80, 🎯 PT2: $1.90 – $2.7,  PT3: $2.80 – $3.70

🚫 Stop: Below $0.75, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast-moving | Technical setup

 recently unveiled AI tool to block novel chemical weapon designs, previously expanded NIH-backed AI platform into commercial alcohol use disorder drug discovery, previously identified three Parkinson's disease subtypes and drug targets to accelerate therapeutic development, also recently secured first letter of intent for its immune cell therapy, launched transformer-base platform to secure GenAI, partnered with American Defense International to enhance US. Biodefense capabilities , company is a pre-clinical biotech and AI-powered drug discovery company focused on developing of therapeutics and vaccines, AI-driven diagnostic platforms, and biodefense 

 ✅ $TELO Entry: $1.20 – $1.25

🎯 PT1: $1.50 – $1.90, 🎯 PT2: $2.00 – $2.50, 🎯 PT3: $2.60 – $2.80

🚫 Stop: Below $1.10, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 back to near 52 weak low from recent high, recently announced positive preclinical data data for Telonmir-1 in breast cancer, company focuses on reversing biological aging and degenerative diseases, analyst price target $15, Rodman and Renshaw buy rating, 

✅ $BKYI Entry: $0.65 – $0.70

🎯 PT1: $0.80 – $1.40, 🎯 PT2: $1.50 – $1.80, 🎯 PT3: $1.90 – $2.50

🚫 Stop: Below $0.50, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup

 another rinse and repeat, announced strategic partnership with Visualforma, recently won contract to secure digital identifies for Major Portuguese Municipality, collaboration news to expand its service and Boost cybersecurity with Scandinavian IT distributor IT2Trust, recent partnership with Cloud Distribution to expand IAM and biometric security solutions across the middle east CEO and Chairman reported recent shares purchased, company provides identify & access management and biometric authentication solutions 

 ✅ $MVST Entry: $2.80 – $2.90

🎯 PT1: $3.40 – $3.8, 🎯 PT2: $3.90 – $4.3, 🎯 PT3: $4.40 – $5.00

🚫 Stop: Below $2.60, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast-moving | Technical Setup

 back to support from recent high above 7, recently raised 2025 gross market outlook to 35% while advancing all-solid-state battery and European partnership , company designs, develops and manufactures advanced lithium-ion battery technologies from core cell materials to full battery packs and energy-store systems, their batteries are used for electric commercial vehicles (buses, trucks, specialty vehicles), heavy duty transportation, and utility-scare energy storage systems, analysts strong buy rating, target price $6, 

✅ YCBD Entry: $0.65 – $0.75

🎯 PT1: $1.30 – $2.3, 🎯 PT2: $2.40 – $3.3, 🎯 PT3: $3.40 – $3.80

🚫 Stop: Below $0.50, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast-moving | Technical Setup

 recently announced strategic acquisition of Bluebird Botanicals, previously announced partnership with Bevtalk distribution to expand herbal Oasis THC Selzer distribution across Florida, US based consumer wellness company focuses on CBD and hemp-derived products, have distribution channel via DTC online, $AMZN and retail partners, Maxim group buy rating  

 ✅  $IFRX Entry: $0.90 – $0.95

🎯 PT1: $1.20 – $1.80, 🎯 PT2: $1.90 – $2.6, 🎯 PT3: $2.70 – $3.60

🚫 Stop: Below $0.75, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 recently announced positive phase 2a results of INF904 in treating Hidradenitis Suppurativa and Chronic Spontaneous Urticaria, company focuses on development of complements C5a system (anti-C5a monoclonal antibody vilobelimab and oral C5aR inhibitor INF904) for inflammatory and autoimmune disease such as Hidradenitis Suppurativa and chronic spontaneous Urticaria,  Lucid Capital raised price target to $24 from $3, Guddenheim raised price target to $22 from $10, Leerink Partners buy rating, H.C Wainwright buy rating, price target $6 

✅ $ENLV Entry: $1.05 – $1.15

🎯 PT1: $1.40 – $1.80, 🎯 PT2: $1.90 – $2.60, 🎯 PT3: $2.70 – $3.80

🚫 Stop: Below $0.90, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 ecently closed $212M private placement, expanding digital asset strategy, adopts RAIN token treasury strategy and advances Allocetra knee osteoarthritis program, recently announced positive 6-month topline data, demonstrating durable and persistent pain reduction and improved function in primary age-rated patients with mod to severe knee osteoarthritis, company focuses on immunotherapy, main program is Allocetra, an off the shelf macrophage-reprogramming therapy intended to restore macrophages to healthy state, treating inflammatory and degenerative disease,  HC Wainwright raised price to #13 from $7 

 ✅ $PRSO Entry: $1.00

🎯 PT1: $1.20 – $1.70, 🎯 PT2: $1.80 – $2.50, 🎯 PT3: $2.60 – $3.20

🚫 Stop: Below $0.80, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 recently announced collaboration with Virewirx, previously secured $1.1M through inducement offer agreement, ,secured $0.9M order from FWA equipment supplier, partnered with WeLink to expand access to high-speed broadband across dense US metro areas, company focuses on fabless semiconductor/mmWave wireless technology, , Benchmark Co buy rating, price target $3, 

✅ $CIGL Entry: $2.00 – $2.05

🎯 PT1: $2.20 – $2.80, 🎯 PT2: $2.90 – $3.30, 🎯 PT3: $3.40 – $3.90

🚫 Stop: Below $1.90, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast-moving | Technical Setup

 recently acquired assets of Software Risk to boost facilities management capabilities, recent partnership with Ryde to open new income streams for drivers in Singapore's growing security and facilities sectors , company provides security and safety solutions to commercial, financial, industrial and government clients 

 ✅ $MRM Entry: $1.60 – $1.70
🎯 PT1: $2.00 – $2.80, 🎯 PT2: $2.90 – $3.40, 🎯 PT3: $3.50 – $3.90
🚫 Stop: Below $1.50, or 2%–5%, or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast-moving | Technical setup 

 back to support from recent high, recently announced that Proof of Human authentications surpasses 20,000 in partnership with WORLD FOUNDATION, co-founded by Sam Altman and Alex Blania, company is a Japan-based holistic healthcare, does have mixed shelf, be mindful on next spike, 

 ✅ $FRGT Entry: $1.35 – $1.40
🎯 PT1: $1.60 – $2.20, 🎯 PT2: $2.30 – $2.80, 🎯 PT3: $2.90 – $3.70
🚫 Stop: Below $1.30, or 2%–5%, or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast-moving | Technical setup 

 small float, recent 1/5 reverse split, announces launching of Zayren Pro with next-generation AI agents, recently announced acquisition of JAK Solar, recent 13g filing shows ATW Fund 9.9% stake, company focuses on building AI-powered freight and supply-chain software, including digital platforms for freight booking and tracking, border shipping apps, transportation management systems (TMS), and real-time GPS/visibility tools across the US and Mexico 

 ✅ $AEHL Entry: $1.15 – $1.20

🎯 PT1: $1.50 – $2.5, 🎯 PT2: $2.60 – $3.2, 🎯 PT3: $3.30 – $3.80

🚫 Stop: Below $1.10, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast-moving | Technical setup

 Another rinse and repeat from recent high, back to support form recent high, previously signed cooperative agreement with BitGo to advance $BIT.X acquisition and security, company focuses on livestream e-commerce, digital/social commerce services, and consulting through its subsidiaries, subsidiaries include a 51% ownership of Hainan Kylin Cloud, does have mixed shelf, be mindful on next spike 

✅ $IMG Entry: $1.00

🎯 PT1: $1.20 – $1.70, 🎯 PT2: $1.80 – $1.90, 🎯 PT3: $2.00 – $2.70

🚫 Stop: Below $0.95, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast-moving | Technical setup

 recent 1/20 reverse split, back to key support also 52wk low, recently announced major computing power contracts and expansion, secured $124M in computing power-related commercial contracts in q4 2025, also its subsidiary previously won spot as supplier candidate in $15.95 M Guangzhou Bank tender, expanded $BIT.X holdings to 730, Company is a digital health and sales developing 

 ✅ $THH entry: $0.60

🎯 PT1: $0.80 – $1.40, 🎯 PT2: $1.50 – $1.80, 🎯 PT3: $1.90 – $3.20

🚫 Stop: Below $0.55, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup

 mj ticker , one of the largest Canadian cannabis companies focuses on production, distribution, and sale of medical and recreational cannabis, also carries non-THC products including hemp-derived wellness goods, Bernstein price target $2.50, does have mixed shelf, be mindful on next spike, 

✅ GTBP Entry: $0.70

🎯 PT1: $1.30 – $1.80, 🎯 PT2: $2.00 – $2.6, 🎯 PT3: $2.70 – $3.30

🚫 Stop: Below $0.60, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 recently announced advancing phase 1 trial of GTB-3650 for relapsed blood cancers, update data expecting Q1 2026, other upcoming catalysts: 1) submission for GTB-5550 trial expected January 2026, have until May 16, 2026 to regain compliance, company develops cancer therapies using proprietary TriKE platform, designed to activate natural killer cells to attack cancer cells,  ROTH MKM price target $8, does have mixed shelf, be mindful on next spike, keep current support .60 as bottom stop loss 

 ✅  CGC Entry: $1.10 – $1.20

🎯 PT1: $1.50 – $1.90, 🎯 PT2: $2.00 – $2.7,🎯 PT3: $2.80 – $3.70

🚫 Stop: Below $1.00, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical setup

 mj ticker , one of the largest Canadian cannabis companies focuses on production, distribution, and sale of medical and recreational cannabis, also carries non-THC products including hemp-derived wellness goods, Bernstein price target $2.50, does have mixed shelf, be mindful on next spike, 

 ✅ $OPAD potential entry: $1.25 – $1.35
🎯 PT1: $1.60– $1.80🎯 PT2: $1.90 – $2.40🎯 PT3: $2.50 – $3.50
🚫 Stop: Below $1 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup 

 back to support from recent high, offering at $1.80, previously secured $4.8M AI robot sales deal, recent reveres split, ultra small float, company offers corporate business training, consulting, advisory and transaction services in China , Alliance global partners price target 3.50

 ✅  CGC Entry: $1.10 – $1.20

🎯 PT1: $1.50 – $1.90, 🎯 PT2: $2.00 – $2.7,🎯 PT3: $2.80 – $3.70

🚫 Stop: Below $1.00, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical setup

 mj ticker , one of the largest Canadian cannabis companies focuses on production, distribution, and sale of medical and recreational cannabis, also carries non-THC products including hemp-derived wellness goods, Bernstein price target $2.50, does have mixed shelf, be mindful on next spike, 

✅ CYN Entry: $2.35 – $2.45

🎯 PT1: $2.80 – $3.3, 🎯 PT2: $3.40 – $3.8,🎯 PT3: $3.90 – $4.50

🚫 Stop: Below $2.25, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical setup

back to near 52wk low from recent high,  recently expanded dealer network with Candler Automation for DriveMod Tugger in agriculture, announced to deliver additional autonomous vehicles to G&J Pepsi , company focuses on industrial automation, mainly self-driving software and solutions for material handling, warehousing, and industrial fleets, its core products include the Enterprise Autonomy Suite, DriveMod modular autonomous tech and fleet management tools, does have mixed shelf, be mindful on next spike 

 ✅ RUBI Entry: $0.8/.85

🎯 PT1: $1.30 – $1.7, 🎯 PT2: $1.80 – $2.5, 🎯 PT3: $2.60 – $3.20

🚫 Stop: Below $0.75, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical setup

recent offering $.60/share, previously signed letter of intent to acquire newbuilding mega Yacht, recent 1/30 reverse split, ultra small float <1m, international shipping company operating in the marine transportation sector 

✅ ONCO Entry: $1.35 – $1.45

🎯 PT1: $1.70 – $2.3, 🎯 PT2: $2.40 – $2.9, 🎯 PT3: $3.00 – $3.60

🚫 Stop: Below $1.00, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical setup

 back to support form recent high, company focuses on research, developments and commercialization of innovative solutions in men's health oncology (cancer diagnostics/treatments), key assets include: 1) Proclarix, an in vitro protein-based diagnostic test for prostate cancer, 2) ENTADFI, a combining finasteride and tadalafil ,  FDA-approved once daily for benign prostatic hyperplasia (BPH),  does have mixed shelf, be mindful on next spike 

 ✅ $APM potential entry: $1.00 – $1.05

🎯 PT1: $1.20 – $1.6, 🎯 PT2: $1.70 – $2.2 🎯 PT3: $2.30 – $2.80

🚫 Stop: Below $0.80, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 recently unveiled new plasma microRNA biomarket data at Alzheimer's conference,   company focuses on targeting disease with unmet medical needs in oncology and infectious diseases. 

✅ $ONCY potential entry: $0.90 – $0.95

🎯 PT1: $1.20 – $1.80, 🎯 PT2: $1.90 – $2.50, 🎯 PT3: $2.60 – $3.80

🚫 Stop: Below $0.80, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup  back to near support from recent high  back to support from recent high, company focuses on the development of first in class intravenously delivered oncolytic virus designed to selectively destroy cancer cells and stimulate the immune system against tumors, previously announced promising Pelareorep data in colorectal cancer, FDA recently agreed on phase 3 trial design for elareorep in pancreatic cancer, planning to launch immunotherapy trial in pancreatic cancer in 2026,  Lake Street buy rating,  RBC Capital buy rating, HC Wainwright raised target price to $10 from $5 

 ✅ $NNVC potential entry: $1.05 – $1.10

🎯 PT1: $1.40 – $1.80, 🎯 PT2: $1.90 – $2.50, 🎯 PT3: $2.60 – $3.30

🚫 Stop: Below $1.00, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 near 52 wk low from recent high above 2,  recently signed Master services agreements with Only Orphans Cote, company focuses on discovering and developing broad-spectrum antiviral therapeutics, former runner, Alliance Global buy rating 

✅ $ARBE potential entry: $1.30 – $1.40

🎯 PT1: $1.60 – $2.5, 🎯 PT2: $2.60 – $3.2, 🎯 PT3: $3.30 – $3.70

🚫 Stop: Below $1.20, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical Setupback to support from recent high above 2.50,  back to near support from recent high above 2.50, company develops 4D imaging radar chipsets and perception radar solutions for automotive, drones, industrial and robotics markets, company attempts to target a global market in automotive OEMS, tier-1 auto suppliers, autonomous/commercial vehicles, robotics, even drones, Canaccord Genuity buy rating, Roth MKM buy rating 

 ✅ NXDR Entry: $1.90 – $2.00
🎯 PT1: $2.30 – $2.80, 🎯 PT2: $2.90 – $3.50, 🎯 PT3: $3.60 – $3.80, 🎯 Long-term: $20+++
🚫 Stop: Below $1.80, or 2%–5%, or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup  

 back to support from recent high above 3.70, potential for longer-term hold, still early post-IPO with long term targets above $20++, company provides an online forum, a neighborhood social networking platform that connects neighbors, local businesses, and public agencies including marketplace for goods and services, recently announced partnership with Waze to bring real-time traffic and road alerts to neighbors, Craigh-Hallum buy rating, hedge fund manager Erick Jackson of EMJ Capital long term price target $374, potential the next 100x runner,  

 ✅ CGTX Entry: $1.30 – $1.40
🎯 PT1: $1.60 – $1.80, 🎯 PT2: $1.90 – $2.70, 🎯 PT3: $2.80 – $3.50
🚫 Stop: Below $1.00, or 2%–5%, or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup  recently entered partnership with  back to support from recent high above 2.50, clinical stage biopharmaceutical company focuses on age-related neurodegenerative diseases specifically Alzheimer's and dementia with Lew bodies, lead candidate is zervimesine (CT1812), oral formulation designed to penetrate the blood-brain barrier and target pathways implicated in neurodegeneration, HC Wainwright price target $3, B. Riley Securities raised price target to $3, does have mixed shelf, be mindful on next spike 

 ✅ IKT Entry: $1.60 – $1.65

🎯 PT1: $1.90 – $2.40, 🎯 PT2: $2.50 – $2.8, 🎯 PT3: $2.90 – $3.40

🚫 Stop: Below $1.40, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 company focuses on minimally invasive treatments for chronic obstructive pulmonary disease (COPD) and severe emphysema, D. Boral Capital price target $14, Stifel Nicolaus buy rating, Lake Street price target $4, Canaccord Genuity buy rating, does have mixed shelf, be mindful on next spike 

✅ YCBD Entry: $1.00 – $1.10

🎯 PT1: $1.40 – $2.30, 🎯 PT2: $2.40 – $3.30, 🎯 PT3: $3.40 – $3.80

🚫 Stop: Below $0.90, or 2%–5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical Setup

 YCBD Another rinse and repeat from recent high above 2.40,  recently entered partnership with Bevtalk distribution to expand herbal Oasis THC Selzer distribution across Florida, US based consumer wellness company focuses on CBD and hemp-derived products, have distribution channel via DTC online, $AMZN and retail partners, Maxim group by rating 

 ✅ $LUNG potential entry $2.10 to $2.20

🎯 Potential PT1: $2.50 to $2.80, 🎯 PT2: $2.90 to $3.50, 🎯 PT3: $3.60 to $4.30

🚫 Potential Stop: below $2.00, or 2% to 5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | fast moving | technical setup

 company focuses on minimally invasive treatments for chronic obstructive pulmonary disease (COPD) and severe emphysema, D. Boral Capital price target $14, Stifel Nicolaus buy rating, Lake Street price target $4, Canaccord Genuity buy rating, does have mixed shelf, be mindful on next spike 

✅ $QNCX potential entry $2.80 – $2.90

🎯 Potential PT1: $3.30 – $3.70, 🎯 PT2: $3.80 – $4.20, 🎯 PT3: $4.30 – $4.80

🚫 Potential Stop: below $2.70, or 2% to 5%, or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 back to support from recent high above 4, company focuses on rare diseases in pediatric and immune-related disorders, upcoming catalyst: phase 3 NEAT trial topline data Q1 2026, NDA filing 2nd half of 2026, report reported positive early clinical data, D. Boral Capital price target $5, Oppenheimer buy rating, Citizens JMP buy rating 

 ✅ $HOUR potential entry $1.80 to $1.85

🎯 Potential PT1: $2.00 to $2.50, 🎯 PT2: $2.60 to $3.30, 🎯 PT3: $3.40 to $3.80

🚫 Potential Stop: below $1.70, or 2% to 5%, or daily max risk per trade

🚦 Risk Level: 🔴 High | fast moving | technical setup

 back to consolidation from recent high, previously announced partnership with Return helper for supply chain boost, company focuses on selling a broad range of consumer products 

✅ $XELB potential entry $1.05 to $1.10

🎯 Potential PT1 $1.40 to $1.80, 🎯 PT2 $1.90 to $2.40, 🎯 PT3 $2.50 to $3.20

🚫 Potential Stop below $1.00, or 2% to 5%, or daily max risk per trade

🚦 Risk Level 🔴 High | fast moving | technical setup

 back to support from recent high, company focuses on medica and consumer products, designing, licensing, marketing and selling branded products, band portfolio includes Halston, Judity Ripka, C Wonder, TowerHill by Christie Brinkley, Longaberger and others across apparel, footwear, accessories, home goods, CEO Robert D'Loren and Director Mark DiSanto recently purchased shares, Noble Financial buy rating 

 USEG potential entry: $0.95 – $1.00

🎯 PT1: $1.20 – $1.70, 🎯 PT2: $1.80 – $2.40, 🎯 PT3: $2.50 – $3.30

🚫 Stop: Below $0.91 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast-moving | Technical Setup

  back 52 wk low from recent high, energy/oil ticker, CEO recently purchased shares, D. Boral Capital price target $3, does have mixed shelf, be mindful on next spike, 

✅ BRN potential entry: $1.05 – $1.10

🎯 PT1: $1.40 – $1.80, 🎯 PT2: $1.90 – $2.30, 🎯 PT3: $2.40 – $3.30

🚫 Potential Stop: Below $1.00 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast-moving | Technical Setup

 back to support from recent high, energy/oil ticker 

 ✅ $WAI Entry: $2.00, 🎯 PT1: $2.30 – $2.9, 🎯 PT2: $3.10 – $3.6, 🎯 PT3: $3.70 – $4.20

🚫 Stop: Below $1.85 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical Setup

 back to support from recent high, recently secured $4.8M AI robot sales deal, recent reveres split, ultra small float, company offers corporate business training, consulting, advisory and transaction services in China 

✅ $CMND Entry: $1.80

🎯 PT1: $2.10 – $2.60, 🎯 PT2: $2.70 – $3.3, 🎯 PT3: $3.40 – $4.80

🚫 Stop: Below $1.75 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 back to 52wk low, recent 1/40 reverse split, recently reported positive data for CMND - 100 in alcool use disorder trial, recently enrolled last patient for first cohort of CMND-100 trial for the treatment of AUD (alcohol use disorder) , recently filed and announced publication of US patent application on binge drinking addiction and compulsive behaviors, also blished international patent application for therapy targeting obesity and metabolic syndrome in collaboration with SciSparc, also recently secured IRB approval from Hadassah Medical Center for phase 1/2a trial of Novel AUD treatment, company focuses on the development of psychedelic-derived therapeutics for mental health, neurological disorders, lead candidate, CMND-100 for alcohol use disorder (AUD)